NCT07223424 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07223424
Title	Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)
Acronym	PSI-Immune
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Diwakar Davar
Indications	colorectal cancer renal cell carcinoma lung non-small cell carcinoma gastric adenocarcinoma Advanced Solid Tumor Merkel cell carcinoma endometrial carcinoma esophagus adenocarcinoma melanoma transitional cell carcinoma skin squamous cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer esophageal cancer cervical cancer hepatocellular carcinoma
Therapies	Pembrolizumab Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST